Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: a case series;L’hydroxocobalamine pour le traitement de la vasoplégie associée à la chirurgie cardiaque : une série de cas

Canadian Journal of Anesthesia

Volumn 65, Issue 5, 2018, Pages 560-568

  Shah, Pranav R ^a   Reynolds, Penny S ^a,b   Pal, Nirvik ^a   Tang, Daniel ^a   McCarthy, Harry ^a   Spiess, Bruce D ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXOCOBALAMIN; HYPERTENSIVE FACTOR;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOPULMONARY BYPASS; CARDIOVASCULAR MORTALITY; CASE STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; EUROSCORE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SURGERY; HEMODYNAMICS; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL PARAMETERS; MORTALITY RISK; NOREPINEPHRINE EQUIVALENT RATE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REFRACTORY HYPOTENSION; RETROSPECTIVE STUDY; SEX RATIO; SINGLE DRUG DOSE; TIME TO TREATMENT; TREATMENT RESPONSE; VASOPLEGIA; ADVERSE EVENT; AGED; ARTERIAL PRESSURE; DRUG EFFECT; MIDDLE AGED;

ADULT; AGED; ARTERIAL PRESSURE; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FEMALE; HUMANS; HYDROXOCOBALAMIN; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VASOPLEGIA;

EID: 85037631593     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-017-1029-3     Document Type: Article

References (30)

1. Egi M, Bellomo R, Langenberg C, et al. Selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: a systematic literature review. Ann Thorac Surg 2007; 83: 715-23.
2. Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2016. https://doi.org/10.1002/14651858.CD003709.pub4.
3. Levin MA, Lin HM, Castillo JG, et al. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegia syndrome. Circulation 2009; 120: 1664-71.
4. Leyh RG, Kofidis T, Strüber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003; 125: 1426-31.
5. Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg 2010; 22: 140-4.
6. Mittnacht AJ, Fischer GW, Reich DL. Methylene blue administration is associated with decreased cerebral oximetry values. Anesth Analg 2007; 105: 549-50.
7. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77: 496-9.
8. Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006; 103: 2-8.
9. Özal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005; 79: 1615-9.
10. Liu H, Yu L, Tang L, Green MS. Vasoplegic syndrome: an update on perioperative considerations. J Clin Anesth 2017; 40: 63-71.
11. Jubran A. Pulse oximetry. Crit Care 1999; 3: R11-7.
12. Roderique JD, Van Dyck K, Holman B, Tang D, Chui B, Spiess BD. The use of high-dose hydroxocobalamin for vasoplegic syndrome. Ann Thorac Surg 2014; 97: 1785-6.
13. Klemm S, Glienke C. Evaluation of hydroxocobalamin in vasoplegia in cardiac surgery. Crit Care Med 2016. https://doi.org/10.1097/01.ccm.0000508898.30711.31.
14. Woehlck HJ, Boettcher BT, Lauer KK, et al. Hydroxocobalamin for vasoplegic syndrome in liver transplantation: restoration of blood pressure without vasospasm. A A Case Rep 2016; 7: 247-50.
15. Burnes ML, Boettcher BT, Woehlck HJ, Zundel MT, Igbal Z, Pagel PS. Hydroxocobalamin as a rescue treatment for refractory vasoplegic syndrome after prolonged cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2017; 31: 1012-4.
16. Boettcher BT, Woehlck HJ, Reck SE, et al. Treatment of vasoplegic syndrome with intravenous hydroxocobalamin during liver transplantation. J Cardiothorac Vasc Anesth 2016; 31: 1381-4.
17. Agha RA, Fowler AJ, Rajmohan S, Barai I. Orgill DP; PROCESS Group. Preferred reporting of case series in surgery: the PROCESS guidelines. Int J Surg 2016; 36: 319-23.
18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-81.
19. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res 2001; 29: 374-93.
20. Jones BL, Nagin DS. Advances in group-based trajectory modeling and a SAS procedure for estimating them. Ann Am Acad Pol Soc Sci 2007; 35: 542-71.
21. Andruff H, Carraro N, Thompson A, Gaudreau P, Louvet B. Latent class growth modelling: a tutorial. Tutor Quant Methods Psychol 2009; 5: 11-24.
22. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-87.
23. Brown SM, Lanspa MJ, Jones JP, et al. Survival after shock requiring high-dose vasopressor therapy. Chest 2013; 143: 664-71.
24. Mekontso-Dessap A, Houël R, Soustelle C, Kirsch M, Thébert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001; 71: 1428-32.
25. Warner MA, Mauermann WJ, Armour S, Barbara DW. Red urinary discolouration following hydroxocobalamin treatment for vasoplegic syndrome. Can J Anesth 2017; 64: 673-4.
26. Leone M, Asfar P, Radermacher P, Vincent JL, Martin C. Optimizing mean arterial pressure in septic shock: a critical reappraisal of the literature. Crit Care 2015; 19: 101.
27. Parrillo JE. Septic shock - vasopressin, norepinephrine, and urgency. N Engl J Med 2008; 358: 954-6.
28. Stellpflug SJ, Gardner RL, Leroy JM, Ellsworth H, Zwank MD. Hydroxocobalamin hinders hemodialysis. Am J Kidney Dis 2013; 62: 395.
29. Mignini MA, Piacentini E, Dubin A. Peripheral arterial blood pressure monitoring adequately tracks central arterial blood pressure in critically ill patients: an observational study. Crit Care 2006; 10: R43.
30. Shanmugam G. Vasoplegic syndrome - the role of methylene blue. Eur J Cardiothorac Surg 2005; 28: 705-10.